Where Are Nucleic Acid Therapeutics Heading? — Trends in Next-Generation Drug Discovery and Luxna Biotech’s Perspective (Featuring a Contribution by our President & CEO, Hideaki Sato) 2026/06/12 Notice > Interview Read
President & CEO, Hideaki Sato, to Speak at a Special Lecture at “INTERPHEX JAPAN 2026 – Pharmaceutical & Cosmetic Manufacturing Expo” 2026/05/19 Event Read
Luxna Biotech and KH Neochem Launch Joint Research to Advance Next-Generation Deliverable Nucleic Acid Therapeutics 2026/03/30 Notice Read
Announcement of License Agreement with Inabata & Co., Ltd. regarding the Manufacture and Sales of the Xeno-Modified Nucleic Acid Amidite “GuNA™” 2026/03/13 Notice Read
